Literature DB >> 16819321

Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.

David M Dorfman1, Julia A Brown, Aliakbar Shahsafaei, Gordon J Freeman.   

Abstract

Programmed death-1 (PD-1), a member of the CD28 costimulatory receptor family, is expressed by germinal center-associated T cells in reactive lymphoid tissue. In a study of a wide range of lymphoproliferative disorders, neoplastic T cells in 23 cases of angioimmunoblastic lymphoma were immunoreactive for PD-1, but other subtypes of T cell and B cell non-Hodgkin lymphoma, as well as classic Hodgkin lymphoma, did not express PD-1. The pattern of PD-1 immunostaining of neoplastic cells in angioimmunoblastic lymphoma was similar to that reported for CD10, a recently described marker of neoplastic T cells in angioimmunoblastic lymphoma. Tumor-associated follicular dendritic cells in cases of angioimmunoblastic lymphoma were found to express PD-L1, the PD-1 ligand. In addition, PD-1-positive reactive T cells formed rosettes around neoplastic L&H cells in 14 cases of nodular lymphocyte predominant Hodgkin lymphoma studied. These findings, along with data from previous studies, suggest that angioimmunoblastic lymphoma is a neoplasm of germinal center-associated T cells and that there is an association of germinal center-associated T cells and neoplastic cells in nodular lymphocyte predominant Hodgkin lymphoma. PD-1 is a useful new marker for angioimmunoblastic lymphoma and lends further support to a model of T-cell lymphomagenesis in which specific subtypes of T cells may undergo neoplastic transformation and result in specific, distinct histologic, immunophenotypic, and clinical subtypes of T-cell neoplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16819321      PMCID: PMC3137919          DOI: 10.1097/01.pas.0000209855.28282.ce

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

Review 1.  The B7-CD28 superfamily.

Authors:  Arlene H Sharpe; Gordon J Freeman
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

2.  T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells.

Authors:  Tatyana Chtanova; Stuart G Tangye; Rebecca Newton; Nita Frank; Martin R Hodge; Michael S Rolph; Charles R Mackay
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

3.  Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells.

Authors:  A Braeuninger; R Küppers; J G Strickler; H H Wacker; K Rajewsky; M L Hansmann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

4.  Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells.

Authors:  T Marafioti; M Hummel; I Anagnostopoulos; H D Foss; B Falini; G Delsol; P G Isaacson; S Pileri; H Stein
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

5.  Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas.

Authors:  David M Dorfman; Harvey A Greisman; Aliakbar Shahsafaei
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

6.  Expression of B-lymphocyte-associated transcription factors in human T-cell neoplasms.

Authors:  Teresa Marafioti; Stefano Ascani; Karen Pulford; Elena Sabattini; Milena Piccioli; Margaret Jones; Pier Luigi Zinzani; Georges Delsol; David Y Mason; Stefano A Pileri
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

7.  Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.

Authors:  Julia A Brown; David M Dorfman; Feng-Rong Ma; Elizabeth L Sullivan; Oliver Munoz; Clive R Wood; Edward A Greenfield; Gordon J Freeman
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

8.  T-bet, a T-cell-associated transcription factor, is expressed in a subset of B-cell lymphoproliferative disorders.

Authors:  David M Dorfman; Eun Sook Hwang; Aliakbar Shahsafaei; Laurie H Glimcher
Journal:  Am J Clin Pathol       Date:  2004-08       Impact factor: 2.493

9.  Characteristic proliferations of reticular and dendritic cells in angioimmunoblastic lymphoma.

Authors:  D Jones; J L Jorgensen; A Shahsafaei; D M Dorfman
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

10.  Differential expression of T-bet, a T-box transcription factor required for Th1 T-cell development, in peripheral T-cell lymphomas.

Authors:  David M Dorfman; Peter van den Elzen; Andrew P Weng; Aliakbar Shahsafaei; Laurie H Glimcher
Journal:  Am J Clin Pathol       Date:  2003-12       Impact factor: 2.493

View more
  100 in total

1.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

2.  PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity.

Authors:  Victor Peña-Cruz; Sean M McDonough; Felipe Diaz-Griffero; Christopher P Crum; Ruben D Carrasco; Gordon J Freeman
Journal:  J Invest Dermatol       Date:  2010-05-06       Impact factor: 8.551

3.  Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder.

Authors:  Benjamin Kaffenberger; Brad Haverkos; Kelly Tyler; Henry K Wong; Pierluigi Porcu; Alejandro Ariel Gru
Journal:  Am J Dermatopathol       Date:  2015-08       Impact factor: 1.533

Review 4.  T Follicular Regulatory Cells and Antibody Responses in Transplantation.

Authors:  Elizabeth F Wallin
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

Review 5.  Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Authors:  Kim A Reiss; Patrick M Forde; Julie R Brahmer
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

Review 6.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

7.  Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas.

Authors:  Yenlin Huang; Anne Moreau; Jehan Dupuis; Berthold Streubel; Barbara Petit; Steven Le Gouill; Nadine Martin-Garcia; Christiane Copie-Bergman; Fanny Gaillard; Marwan Qubaja; Bettina Fabiani; Giovanna Roncador; Corinne Haioun; Marie-Hélène Delfau-Larue; Teresa Marafioti; Andreas Chott; Philippe Gaulard
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

Review 8.  The role of B7 family molecules in hematologic malignancy.

Authors:  Paul Greaves; John G Gribben
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

9.  PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis.

Authors:  Chandra Krishnan; Roger A Warnke; Daniel A Arber; Yasodha Natkunam
Journal:  Am J Surg Pathol       Date:  2010-02       Impact factor: 6.394

10.  Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection.

Authors:  Henry Radziewicz; Chris C Ibegbu; Huiming Hon; Melissa K Osborn; Kamil Obideen; Mohammad Wehbi; Gordon J Freeman; Jeffrey L Lennox; Kimberly A Workowski; Holly L Hanson; Arash Grakoui
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.